AE37
Phase 2- Indications
- Triple negative breast cancer, Prostate cancer
Company intelligence / Profile preview
NuGenerex Immuno-Oncology
Miramar, Florida, United Statesnugenerexinc.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Phase 2
01
Overview
AE37 (lead product) has shown promising results in Phase II trials for breast cancer, particularly in patients with advanced stage, HER2 under-expression, and triple negative breast cancer. The vaccine demonstrated improved disease-free survival for up to ten years of follow-up. Currently in Phase II trials for metastatic triple negative breast cancer in combination with pembrolizumab (Keytruda).
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Immunotherapeutic peptide vaccines
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Merck Sharpe & Dohme Corp.National Surgical Adjuvant Breast and Bowel Program (NSABP)Shenzhen Bioscien (China)
Beyond the preview
Go deeper on NuGenerex Immuno-Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NuGenerex Immuno-Oncology.